CN117398393A - 12-酮基石胆酸在制备抗缓症链球菌产品中的应用 - Google Patents
12-酮基石胆酸在制备抗缓症链球菌产品中的应用 Download PDFInfo
- Publication number
- CN117398393A CN117398393A CN202311218485.7A CN202311218485A CN117398393A CN 117398393 A CN117398393 A CN 117398393A CN 202311218485 A CN202311218485 A CN 202311218485A CN 117398393 A CN117398393 A CN 117398393A
- Authority
- CN
- China
- Prior art keywords
- streptococcus mitis
- pharmaceutically acceptable
- ketolithocholic acid
- acceptable salt
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CVNYHSDFZXHMMJ-VPUMZWJWSA-N 12-ketolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)C(=O)C1 CVNYHSDFZXHMMJ-VPUMZWJWSA-N 0.000 title claims abstract description 52
- CVNYHSDFZXHMMJ-UHFFFAOYSA-N 12-keto-lithocholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(=O)C2 CVNYHSDFZXHMMJ-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 241001134658 Streptococcus mitis Species 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 22
- 208000015181 infectious disease Diseases 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims description 9
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 239000000022 bacteriostatic agent Substances 0.000 claims description 4
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 206010042276 Subacute endocarditis Diseases 0.000 claims description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 208000008494 pericarditis Diseases 0.000 claims description 3
- 206010034674 peritonitis Diseases 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124532 absorption promoter Drugs 0.000 claims 1
- -1 absorption promoters Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 14
- 241000894006 Bacteria Species 0.000 abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 208000001050 sialadenitis Diseases 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229910021487 silica fume Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于生物制药技术领域,公开了12‑酮基石胆酸在制备抗缓症链球菌产品中的应用,具体公开了12‑酮基石胆酸或其药学上可接受的盐在制备抗缓症链球菌感染产品中的应用。本发明首次发现了12‑酮基石胆酸具有抑制缓症链球菌活性的作用。通过测定抑制50%受试菌所需最低抑菌浓度,结果表明,12‑酮基石胆酸对缓症链球菌的MIC50为2.635μg/mL。12‑酮基石胆酸可作为抑制缓症链球菌的药物,为临床防治缓症链球菌引起的疾病提供新思路。
Description
技术领域
本发明属于生物制药技术领域,具体涉及12-酮基石胆酸在制备抗缓症链球菌产品中的应用。
背景技术
缓症链球菌(Streptococcus mitis)属于α-溶血性链球菌(亦称甲型溶血性链球菌),通常是人体口腔、消化道、生殖道等部位的正常菌群之一,该菌是一种条件致病菌,可致中毒性休克综合征,亚急性心内膜炎,前列腺炎等,此外,还可致肺炎、心包炎、腹膜炎、唾腺炎、口面部感染、牙源性感染、中耳炎、鼻窦炎等。据报道在发病猪体内分离到此病原菌,并且导致仔猪发病和死亡严重,说明缓症链球菌对猪也是有致病性。在儿科常用抗生素中,缓症链球菌对氨曲南、头孢曲松、哌拉西林/他唑巴坦、阿莫西林/克拉维酸钾均有不同程度耐药,耐药率达到42.3%~48.1%。这些抗生素目前仍然是儿童肺炎的常用药物。细菌耐药是全球问题,但相应的抗生素的开发则进展缓慢,形势非常严峻,因此迫切需要一种新的抗菌药物或抗菌产品来抑制细菌。
胆汁酸是胆汁中的一个有效成分,是参与胆汁消化功能的重要成分之一。其含量变化在肝脏病诊断中具有重要的参考价值,此外还具有抑制肿瘤的效果。12-酮基石胆酸(12-Ketolithocholic Acid)是肠道中的次级胆汁酸之一,但是目前未见12-酮基石胆酸在制备缓症链球菌产品中应用的报道。
发明内容
本发明第一方面的目的,在于提供12-酮基石胆酸或其药学上可接受的盐在制备抗缓症链球菌感染产品中的应用。
本发明第二方面的目的,在于提供12-酮基石胆酸或其药学上可接受的盐在抗缓症链球菌感染中的应用。
本发明第三方面的目的,在于提供12-酮基石胆酸或其药学上可接受的盐在制备用于抑制缓症链球菌活性的产品中的应用。
本发明第四方面的目的,在于提供12-酮基石胆酸或其药学上可接受的盐在抑制缓症链球菌活性中的应用。
本发明第五方面的目的,在于提供12-酮基石胆酸或其药学上可接受的盐在制备用于预防和/或治疗由缓症链球菌感染所致疾病的产品中的应用。
本发明第六方面的目的,在于提供一种产品。
本发明第七方面的目的,在于提供一种抑制缓症链球菌活性的方法。
为了实现上述目的,本发明所采取的技术方案是:
本发明第一个方面,在于提供12-酮基石胆酸或其药学上可接受的盐在制备抗缓症链球菌感染产品中的应用。
在本发明一些实施方式中,所述产品包括抑菌剂和药物。
在本发明一些实施方式中,所述12-酮基石胆酸或其药学上可接受的盐的浓度为2~75μg/mL。
本发明第二个方面,在于提供12-酮基石胆酸或其药学上可接受的盐在抗缓症链球菌感染中的应用。
在本发明一些实施方式中,所述12-酮基石胆酸或其药学上可接受的盐的浓度为2~75μg/mL。
本发明第三个方面,在于提供12-酮基石胆酸或其药学上可接受的盐在制备用于抑制缓症链球菌活性的产品中的应用。
在本发明一些实施方式中,所述产品包括抑菌剂和药物。
在本发明一些实施方式中,所述12-酮基石胆酸或其药学上可接受的盐的浓度为2~75μg/mL。
本发明第四个方面,在于提供12-酮基石胆酸或其药学上可接受的盐在抑制缓症链球菌活性中的应用。
在本发明一些实施方式中,所述12-酮基石胆酸或其药学上可接受的盐的浓度为2~75μg/mL。
本发明第五个方面,在于提供12-酮基石胆酸或其药学上可接受的盐在制备用于预防和/或治疗由缓症链球菌感染所致疾病的产品中的应用。
在本发明一些实施方式中,所述产品包括抑菌剂和药物。
在本发明一些实施方式中,所述12-酮基石胆酸或其药学上可接受的盐的浓度为2~75μg/mL。
在本发明一些实施方式中,所述疾病包括中毒性休克综合征、亚急性心内膜炎、前列腺炎、肺炎、心包炎、腹膜炎、唾腺炎、口面部感染、牙源性感染、中耳炎和鼻窦炎中的至少一种。
本发明第六个方面,在于提供一种产品,包括12-酮基石胆酸或其药学上可接受的盐和药学可接受的辅料。
在本发明一些实施方式中,所述药学可接受的辅料包括填充剂、崩解剂、稀释剂、润滑剂、粘合剂、湿润剂、矫味剂、助悬剂、溶剂、缓释剂、乳化剂、吸收促进剂、表面活性剂或防腐剂中的至少一种。
在本发明一些实施方式中,所述填充剂选自淀粉、蔗糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素或葡萄糖等;所述粘合剂选自纤维素衍生物、藻酸盐、淀粉、水、糊精、明胶、羟丙基纤维素、甲基纤维素或聚乙烯吡咯烷酮等;所述稀释剂选自乳糖、蔗糖、甘露醇、玉米淀粉、马铃薯淀粉、磷酸钙、柠檬酸钙和结晶纤维素中的至少一种;所述崩解剂选自玉米淀粉、马铃薯淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙基纤维素、羧甲基淀粉钠、羧甲基纤维素、交联羧甲基纤维素钠、羧甲基纤维素钙和藻酸中的至少一种;所述润滑剂选自硬脂酸、聚乙二醇、碳酸钙、碳酸氢钠、微粉硅胶、滑石粉、无水硅胶和硬脂酸镁中的至少一种:所述助悬剂选自微粉硅胶、蜂蜡、纤维素、羧甲基纤维素钠和固态聚乙二醇中的至少一种:所述润湿剂选自甘油、吐温-80、氧基氢化蓖麻油、十二烷基硫酸钠和卵磷脂中的至少一种:所述溶剂选自乙醇、液态聚乙二醇、异丙醇、吐温-80、甘油、丙二醇和植物油中的至少一种,所述植物油选自大豆油、蓖麻油、花生油、调和油等:所述表面活性剂选自十二烷基苯磺酸钠、硬脂酸、聚氧乙烯-聚氧丙烯共聚物、脂肪酸山梨坦和聚山梨(吐温)中的至少一种:所述矫味剂选自阿斯巴甜、蔗糖素、香精、甜菊素、安赛蜜、柠檬酸和糖精钠中的至少一种;所述防腐剂选自对羟苯甲酸甲酯或对羟苯甲酸丙酯中的至少一种。
在本发明一些实施方式中,所述产品至少具有如下功能之一:
(1)抗缓症链球菌感染;
(2)抑制缓症链球菌活性;
(3)预防或治疗由缓症链球菌感染所致疾病。
本发明第七个方面,在于提供一种抑制缓症链球菌活性的方法,包括使用12-酮基石胆酸或其药学上可接受的盐或本发明第六方面的产品处理缓症链球菌的步骤。
本发明的有益效果是:
本发明首次发现了12-酮基石胆酸具有抑制缓症链球菌活性的作用。通过测定抑制50%受试菌所需最低抑菌浓度,结果表明,12-酮基石胆酸对缓症链球菌的MIC50为2.635μg/mL。12-酮基石胆酸可作为抑制缓症链球菌的药物,为临床防治缓症链球菌引起的疾病提供新思路。
附图说明
图1为12-酮基石胆酸浓度与缓症链球菌生长抑制率关系图。
具体实施方式
现结合具体实施例对本发明进行详细说明,但不限制本发明的范围。
本实施例中所使用的材料、试剂等,如无特别说明,为从商业途径得到的材料和试剂。
在本发明中,所述12-酮基石胆酸的CAS为5130-29-0,分子式:C24H38O4,分子量:390.56,英文名称:12-Ketolithocholic Acid。所述12-酮基石胆酸的结构式如式I所示;在本发明实施例中,所述脱氧胆酸购自Avanti公司,产品编号为700239P。
实施例1
采用微量肉汤二倍稀释法对12-酮基石胆酸进行了体外抗菌活性测试,考察其对缓症链球菌的抗菌活性,以对照品氯霉素进行实验系统的评价。
1.供试品和对照品
供试品:
名称:12-酮基石胆酸,市售品(产品编号:700239P,品牌:Avanti)。
供试品临用前用乙醇配制成最大浓度50mg/mL,依次对倍稀释。
对照品:
名称:氯霉素,市售品(产品编号:56757,品牌:MACKLIN)。
2.测试菌株及其培养方法
2.1菌株:缓症链球菌ATCC49456,购于北京百欧博伟生物技术有限公司。
2.2培养条件:Todd-Hewitt Broth,37℃孵育24~48小时。
2.3菌种开启接种并培养
用75%酒精棉擦拭西林瓶外部,在安全柜内使用尖嘴钳去除塑料盖及铝盖。缓慢开启胶塞,用75%酒精棉消毒瓶口部分,使用无菌吸管注入0.5mL液体培养基复溶冻干粉末,将悬液接种在培养基上,37℃培养24小时后,挑取单个菌落于液体培养基中在相同的培养条件下培养增菌。
2.4菌液工作液的准备
当OD600值达到0.5左右(约108CFU/mL),经THB肉汤梯度稀释(0、10、100、1 000、10000、100000、10000倍)后,取100μL菌悬液接种于固体培养基上,培养24小时后计数活菌数,计算菌悬液浓度,再将此混悬菌液进行稀释,使菌悬液最终浓度约为2×106CFU/mL。菌种操作均在无菌条件下进行,实验完毕,所有耗材经灭菌再做丢弃处理。
3.抑制50%受试菌所需最低抑菌浓度的测定(MIC50)
3.1测试方法:采取微量肉汤稀释法,进行MIC50的测定。
实验分为阳性对照组(即不含药物的菌悬液)、阴性对照组(含溶媒乙醇的培养基)和实验组(含不同浓度的12-酮基石胆酸菌悬液)。以上各组均设置3个平行组。将浓度为75μg/mL的12-酮基石胆酸实验液按对倍稀释溶于液体培养基中,使其终浓度为75μg/mL、37.5μg/mL、18.75μg/mL、9.375μg/mL、4.6875μg/mL、0μg/mL。浓度为2×10 6CFU·mL-1菌悬液与各组药液按比例1:1各100μL,分别接种于无菌96孔板中,使菌悬液的终浓度为1×10 6CFU/mL(含105CFU/孔),置于适当的培养条件下培养20小时。同时设置对照品氯霉素,使其终浓度分别为32μg/mL、16μg/mL、8μg/mL、4μg/mL、2μg/mL、1μg/mL、0μg/mL。培养结束后,在黑色背景下进行肉眼观察,平皿内未见细菌生长的最低药物浓度即为12-酮基石胆酸的最低抑菌浓度(MIC)。所有菌种的MIC测定实验重复3次。悬浮菌体测OD600值,不同浓度的供试品及对照抑菌率的计算方法:抑菌率(%)=1-(供试品OD值-阴性对照OD值)/(阳性对照OD值-阴性对照OD值)×100%。通过曲线拟合得函数计算而得MIC50。
3.2结果判断
试验结果见表1,抑制率图见图1,当阳性对照孔(即不含药物)内细菌明显生长,试验才有意义。结果显示,阳性对照孔(即不含药物)内细菌正常生长,溶媒对照培养基孔无菌生长。对照品氯霉素对缓症链球菌的MIC值为4μg/mL,符合美国临床实验室标准化委员会(National committee for clinical library standardization,NCCLS)2001年的《抗微生物药物敏感试验的执行标准:第十一版信息增刊》M100-S11中氯霉素对缓症链球菌≤4μg/mL的标准,说明本实验方法是可靠的。
表1不同浓度12-酮基石胆酸对缓症链球菌生长影响的吸光值测定
统计结果表明:12-酮基石胆酸对受试的缓症链球菌的MIC50为2.635μg/mL。
综上所述,12-酮基石胆酸有良好的抑制缓症链球菌活性。
上面结合附图对本发明实施例作了详细说明,但是本发明不限于上述实施例,在所属技术领域普通技术人员所具备的知识范围内,还可以在不脱离本发明宗旨的前提下做出各种变化。此外,在不冲突的情况下,本发明的实施例及实施例中的特征可以相互组合。
Claims (10)
1.12-酮基石胆酸或其药学上可接受的盐在制备抗缓症链球菌感染产品中的应用。
2.12-酮基石胆酸或其药学上可接受的盐在抗缓症链球菌感染中的应用。
3.12-酮基石胆酸或其药学上可接受的盐在制备用于抑制缓症链球菌活性的产品中的应用。
4.12-酮基石胆酸或其药学上可接受的盐在抑制缓症链球菌活性中的应用。
5.12-酮基石胆酸或其药学上可接受的盐在制备用于预防和/或治疗由缓症链球菌感染所致疾病的产品中的应用。
6.根据权利要求1、权利要求3或权利要求5所述的应用,其特征在于,所述产品包括抑菌剂和药物。
7.根据权利要求5所述的应用,其特征在于,所述疾病包括中毒性休克综合征、亚急性心内膜炎、前列腺炎、肺炎、心包炎、腹膜炎、唾腺炎、口面部感染、牙源性感染、中耳炎和鼻窦炎中的至少一种。
8.一种产品,包括12-酮基石胆酸或其药学上可接受的盐和药学可接受的辅料。
9.根据权利要求8所述的抑菌剂,其特征在于,所述药学可接受的辅料包括填充剂、崩解剂、稀释剂、润滑剂、粘合剂、湿润剂、矫味剂、助悬剂、溶剂、缓释剂、乳化剂、吸收促进剂、表面活性剂或防腐剂中的至少一种。
10.一种抑制缓症链球菌活性的方法,包括使用12-酮基石胆酸或其药学上可接受的盐或权利要求8或9所述的产品处理缓症链球菌的步骤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311218485.7A CN117398393A (zh) | 2023-09-20 | 2023-09-20 | 12-酮基石胆酸在制备抗缓症链球菌产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311218485.7A CN117398393A (zh) | 2023-09-20 | 2023-09-20 | 12-酮基石胆酸在制备抗缓症链球菌产品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117398393A true CN117398393A (zh) | 2024-01-16 |
Family
ID=89489935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311218485.7A Pending CN117398393A (zh) | 2023-09-20 | 2023-09-20 | 12-酮基石胆酸在制备抗缓症链球菌产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117398393A (zh) |
-
2023
- 2023-09-20 CN CN202311218485.7A patent/CN117398393A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8097247B2 (en) | Probiotic, lactic acid-producing bacteria and uses thereof | |
McNulty et al. | Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents | |
Wade | Enterococcus faecium in hospitals | |
CN117143783B (zh) | 一种唾液联合乳杆菌vb330及其应用 | |
JP2961182B2 (ja) | クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物 | |
Aydın et al. | Identification and Antimicrobial Susceptibility of Sub Clinical Mastitis Pathogens Isolated From Hair Goats' Milk | |
CN111419829B (zh) | 和厚朴酚在抑制猪链球菌或其生物被膜中的用途 | |
CN117398393A (zh) | 12-酮基石胆酸在制备抗缓症链球菌产品中的应用 | |
JP2000514072A (ja) | プロイロムチリン誘導体の獣医学的使用 | |
Rodriguez | An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media | |
CN117205220A (zh) | 12-酮基石胆酸化合物在制备抗口腔链球菌产品中的应用 | |
CN115252627B (zh) | 一种石胆酸的用途 | |
CN115531394B (zh) | 脱氧胆酸在制备抗缓症链球菌的产品中的应用 | |
CN115381841B (zh) | 一种异石胆酸的用途 | |
Pérez et al. | In vitro penetration of fosfomycin in respiratory cells | |
CN115350198B (zh) | 一种表别石胆酸的用途 | |
RU2415684C2 (ru) | Фармацевтическая композиция для лечения и/или профилактики дисбиозов кишечника в процессе проведения антибактериальной терапии у теплокровных животных: крупного рогатого скота, свиней, домашних животных, в частности собак, кошек, и сельскохозяйственных птиц и способ лечения и/или профилактики дисбиозов кишечника в процессе проведения антибактериальной терапии у теплокровных животных: крупного рогатого скота, свиней, домашних животных, в частности собак, кошек, и сельскохозяйственных птиц | |
Gutierrez et al. | Rothia mucilaginosa, an important cause of invasive disease in children with leukemia: Report of 2 cases and review of the literature | |
CN115531395B (zh) | 脱氧胆酸在制备抗婴儿链球菌的产品中的应用 | |
CN1265594A (zh) | 使用利福霉素衍生物治疗家畜乳腺炎的方法 | |
CN106673989A (zh) | 一种药物组合物及其制备方法和应用 | |
EP3337494B1 (en) | Lysobactin for use in the treatment of bovine mastitis | |
JP2002512196A (ja) | 連鎖球菌製剤 | |
CN115105491A (zh) | 丝氨酸在制备抑制猪链球菌药物中的用途 | |
CN1176657C (zh) | 含有头孢唑啉和β-内酰胺酶抑制剂的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |